20Med Therapeutics and Partners receive Eurostars Grant for the Development of New mRNA Therapeutics for OsteoarthritisWednesday, July 24, 2019
Osteoarthritis, which affects 130 million people worldwide, is characterized by chronic joint pain and functional impairment. OA imposes a huge burden on the individual patient and European health care system. No treatments for OA are available to counteract disease progression. Often total joint replacement is the only therapeutic option.
“With osteoarthritis predicted to be the fourth leading cause of disability worldwide by 2020 and no approved treatments to counteract disease progression, there is an urgent need for new treatment options,” said Dr. Michiel Lodder, CEO of 20Med Therapeutics. “The Eurostar grant will support the development of a novel approach to treating osteoarthritis using bioresponsive polymer-based nanoparticle delivery of stabilized mRNA factors into the joint.”
The consortium’s novel approach to developing new mRNA therapeutics for OA utilizes 20Med’s unique patented nanotechnology combined with Ethris’ proprietary stabilized non-immunogenic mRNA technology – SNIM®. The new therapeutics will be tested in different preclinical models by the consortium partners from Paracelsus Medical University, Salzburg, Austria, and the AO Research Institute Davos (ARI), Switzerland.
About 20Med Therapeutics
20Med Therapeutics is a Dutch biotechnology company developing innovative therapeutics based on its proprietary delivery technology. 20Med’s non-viral delivery platform is based on bioresponsive polymers specifically designed for the efficient intracellular delivery of oligonucleotides.
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
European Medicines Agency validates marketing application for Filgotinib for the treatment of rheumatoid arthritis
European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10